Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.27
GSK's Cash-to-Debt is ranked lower than
80% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. GSK: 0.27 )
Ranked among companies with meaningful Cash-to-Debt only.
GSK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.43 Max: 0.85
Current: 0.27
0.08
0.85
Equity-to-Asset 0.02
GSK's Equity-to-Asset is ranked lower than
97% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.62 vs. GSK: 0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
GSK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.25 Max: 0.37
Current: 0.02
0.02
0.37
Interest Coverage 3.71
GSK's Interest Coverage is ranked lower than
87% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.29 vs. GSK: 3.71 )
Ranked among companies with meaningful Interest Coverage only.
GSK' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.74 Max: 17.51
Current: 3.71
3.71
17.51
Piotroski F-Score: 5
Altman Z-Score: 1.29
Beneish M-Score: -2.74
WACC vs ROIC
9.59%
8.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 9.32
GSK's Operating Margin % is ranked higher than
54% of the 672 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.86 vs. GSK: 9.32 )
Ranked among companies with meaningful Operating Margin % only.
GSK' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 27.93 Max: 43.15
Current: 9.32
9.32
43.15
Net Margin % 3.27
GSK's Net Margin % is ranked lower than
61% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. GSK: 3.27 )
Ranked among companies with meaningful Net Margin % only.
GSK' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 18.96 Max: 35.2
Current: 3.27
3.27
35.2
ROE % 46.73
GSK's ROE % is ranked higher than
96% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.66 vs. GSK: 46.73 )
Ranked among companies with meaningful ROE % only.
GSK' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.26 Max: 179.63
Current: 46.73
17.3
179.63
ROA % 1.61
GSK's ROA % is ranked lower than
62% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.48 vs. GSK: 1.61 )
Ranked among companies with meaningful ROA % only.
GSK' s ROA % Range Over the Past 10 Years
Min: 1.61  Med: 12.76 Max: 18.45
Current: 1.61
1.61
18.45
ROC (Joel Greenblatt) % 25.36
GSK's ROC (Joel Greenblatt) % is ranked higher than
68% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.44 vs. GSK: 25.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GSK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.36  Med: 83.7 Max: 120.14
Current: 25.36
25.36
120.14
3-Year Revenue Growth Rate 1.80
GSK's 3-Year Revenue Growth Rate is ranked lower than
64% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. GSK: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GSK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -4.2  Med: 4.8 Max: 15.3
Current: 1.8
-4.2
15.3
3-Year EBITDA Growth Rate -20.50
GSK's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.70 vs. GSK: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GSK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.6 Max: 17.4
Current: -20.5
-20.5
17.4
3-Year EPS without NRI Growth Rate -44.80
GSK's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. GSK: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GSK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 5 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 5 Warning Signs with GlaxoSmithKline PLC $GSK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GSK's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GSK Guru Trades in Q1 2016

Jeremy Grantham 79,900 sh (New)
Lee Ainslie 28,520 sh (New)
Jim Simons 480,600 sh (+172.45%)
Kahn Brothers 131,950 sh (+55.97%)
John Rogers 1,582,913 sh (+7.17%)
NWQ Managers 498,115 sh (+6.02%)
Charles Brandes 4,474,409 sh (+3.98%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (+1.12%)
Ken Fisher 11,657,855 sh (+1.09%)
First Eagle Investment 1 sh (unchged)
Pioneer Investments 551,520 sh (unchged)
Francis Chou 18,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt 51,331 sh (-1.24%)
Murray Stahl 25,973 sh (-1.42%)
Diamond Hill Capital 151,307 sh (-5.45%)
Tweedy Browne 116,070 sh (-12.81%)
Sarah Ketterer 450,405 sh (-13.10%)
Jeff Auxier 111,282 sh (-18.19%)
HOTCHKIS & WILEY 8,915,323 sh (-26.34%)
Dodge & Cox 81,262 sh (-27.95%)
PRIMECAP Management 1,116,885 sh (-73.72%)
» More
Q2 2016

GSK Guru Trades in Q2 2016

NWQ Managers 2,075,187 sh (+316.61%)
Kahn Brothers 380,335 sh (+188.24%)
Jeremy Grantham 154,880 sh (+93.84%)
Jim Simons 510,800 sh (+6.28%)
John Rogers 1,607,697 sh (+1.57%)
Ken Fisher 11,730,875 sh (+0.63%)
Tweedy Browne 116,491 sh (+0.36%)
Barrow, Hanley, Mewhinney & Strauss 251,800 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Francis Chou 18,000 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Lee Ainslie Sold Out
PRIMECAP Management 1,115,985 sh (-0.08%)
Jeff Auxier 110,732 sh (-0.49%)
Pioneer Investments 543,125 sh (-1.52%)
HOTCHKIS & WILEY 8,439,389 sh (-5.34%)
Charles Brandes 4,224,506 sh (-5.59%)
Sarah Ketterer 329,801 sh (-26.78%)
Dodge & Cox 44,262 sh (-45.53%)
Joel Greenblatt 25,857 sh (-49.63%)
» More
Q3 2016

GSK Guru Trades in Q3 2016

John Hussman 50,000 sh (New)
Jeremy Grantham 1,563,336 sh (+909.39%)
Jim Simons 930,000 sh (+82.07%)
Kahn Brothers 632,040 sh (+66.18%)
NWQ Managers 2,658,155 sh (+28.09%)
Ken Fisher 11,861,172 sh (+1.11%)
Francis Chou 18,000 sh (unchged)
First Eagle Investment 1 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
John Rogers 1,607,697 sh (unchged)
Murray Stahl 25,973 sh (unchged)
Pioneer Investments 542,025 sh (-0.20%)
PRIMECAP Management 1,109,085 sh (-0.62%)
Sarah Ketterer 327,419 sh (-0.72%)
Tweedy Browne 114,844 sh (-1.41%)
Joel Greenblatt 25,284 sh (-2.22%)
HOTCHKIS & WILEY 8,150,402 sh (-3.42%)
Jeff Auxier 105,772 sh (-4.48%)
Dodge & Cox 41,962 sh (-5.20%)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (-6.59%)
Charles Brandes 3,525,668 sh (-16.54%)
» More
Q4 2016

GSK Guru Trades in Q4 2016

John Paulson 296,000 sh (New)
Jim Simons 3,085,500 sh (+231.77%)
Kahn Brothers 833,315 sh (+31.85%)
Jeremy Grantham 1,820,174 sh (+16.43%)
Joel Greenblatt 26,315 sh (+4.08%)
John Rogers 1,646,146 sh (+2.39%)
Pioneer Investments 545,625 sh (+0.66%)
First Eagle Investment 1 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 235,200 sh (unchged)
Diamond Hill Capital 151,307 sh (unchged)
Francis Chou 18,000 sh (unchged)
John Hussman Sold Out
Tweedy Browne 114,437 sh (-0.35%)
Ken Fisher 11,809,500 sh (-0.44%)
PRIMECAP Management 1,093,985 sh (-1.36%)
NWQ Managers 2,568,013 sh (-3.39%)
HOTCHKIS & WILEY 7,807,200 sh (-4.21%)
Murray Stahl 23,973 sh (-7.70%)
Sarah Ketterer 294,560 sh (-10.04%)
Charles Brandes 3,149,621 sh (-10.67%)
Dodge & Cox 36,762 sh (-12.39%)
Jeff Auxier 89,247 sh (-15.62%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:GSK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, OTCPK:BAYRY, NYSE:BMY, NYSE:LLY, NYSE:SNY, NYSE:AZN, NYSE:MRK, OTCPK:ALPMY, NYSE:NVS, OTCPK:OTSKF, OTCPK:CHGCF, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:SNPHY, OTCPK:PTKFY, NAS:GWPH, NYSE:PFE, NAS:AERI » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, OXGSK.Switzerland, GSK.UK, GLAXF.USA,
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by market capitalization. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Guru Investment Theses on GlaxoSmithKline PLC

Ariel Funds Comments on GlaxoSmithKline plc - Sep 28, 2016

In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair.

From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Top Ranked Articles about GlaxoSmithKline PLC

GlaxoSmithKline, Vodafone Hit 3-Year Low Prices 4 stocks that present opportunities to buy
GlaxoSmithKline PLC (NYSE:GSK), Diageo PLC (NYSE:DEO), Vodafone Group PLC (NASDAQ:VOD) and National Grid PLC (NYSE:NGG) have reached their three-year low prices. Read more...
Kahn Brothers Adds to 4 Holdings in 3rd Quarter Largest acquisition is in GlaxoSmithKline
Kahn Brothers (Trades, Portfolio) added to four holdings in its portfolio in the third quarter. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...
Strong Revenue Points to Gains at GlaxoSmithKline Business purchases could be key revenue generators
In the biotech arena, there are few names that attract as much attention as GlaxoSmithKline PLC (NYSE:GSK), which closed at $43.42 on Sept. 23, 2016 (down by 0.37 percent from the previous close). The stock has gyrated in a 52-week range between $37.24 and $45.58, which indicates that valuations are currently at the bullish end of the spectrum. Read more...
Ariel Funds Comments on GlaxoSmithKline plc Guru stock highlight
In addition, GlaxoSmithKline plc (NYSE:GSK) rallied +7.74%1 in the second quarter, after reporting profit growth for the first time since 2013. Glaxo is seeing benefits from its purchase of Novartis’ vaccines unit. Demand for vaccines and new drugs helped offset declines in the sales of blockbuster asthma medication Advair. Read more...
Kahn Brothers Adds to BP, GlaxoSmithKline Stakes Firm founded by Irving Kahn adds to 8 holdings
Legendary investor Irving Kahn, along with his brothers Thomas Graham and Alan Kahn, founded the Kahn Brothers (Trades, Portfolio) Group in 1978, an investment firm that manages more than $800 million in assets. Irving Kahn trained directly with Benjamin Graham and served as his teaching assistant at Columbia Business School. Read more...

Ratios

vs
industry
vs
history
PE Ratio 87.95
GSK's PE Ratio is ranked lower than
87% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.50 vs. GSK: 87.95 )
Ranked among companies with meaningful PE Ratio only.
GSK' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.72 Max: 99999999.99
Current: 87.95
6.35
99999999.99
Forward PE Ratio 15.29
GSK's Forward PE Ratio is ranked higher than
51% of the 89 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.46 vs. GSK: 15.29 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 87.95
GSK's PE Ratio without NRI is ranked lower than
87% of the 581 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.49 vs. GSK: 87.95 )
Ranked among companies with meaningful PE Ratio without NRI only.
GSK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.65 Max: 284.83
Current: 87.95
6.38
284.83
Price-to-Owner-Earnings 14.54
GSK's Price-to-Owner-Earnings is ranked higher than
80% of the 296 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.92 vs. GSK: 14.54 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GSK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.81  Med: 15.12 Max: 125.21
Current: 14.54
4.81
125.21
PB Ratio 72.97
GSK's PB Ratio is ranked lower than
99% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.93 vs. GSK: 72.97 )
Ranked among companies with meaningful PB Ratio only.
GSK' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.35 Max: 610.36
Current: 72.97
5.48
610.36
PS Ratio 2.93
GSK's PS Ratio is ranked lower than
51% of the 727 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.85 vs. GSK: 2.93 )
Ranked among companies with meaningful PS Ratio only.
GSK' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.79 Max: 3.97
Current: 2.93
1.94
3.97
Price-to-Free-Cash-Flow 19.78
GSK's Price-to-Free-Cash-Flow is ranked higher than
57% of the 228 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.42 vs. GSK: 19.78 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GSK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 17.15 Max: 135.68
Current: 19.78
8.24
135.68
Price-to-Operating-Cash-Flow 12.60
GSK's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.18 vs. GSK: 12.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GSK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.61  Med: 12.01 Max: 27.31
Current: 12.6
6.61
27.31
EV-to-EBIT 40.19
GSK's EV-to-EBIT is ranked lower than
79% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. GSK: 40.19 )
Ranked among companies with meaningful EV-to-EBIT only.
GSK' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.7 Max: 72.6
Current: 40.19
6.3
72.6
EV-to-EBITDA 24.04
GSK's EV-to-EBITDA is ranked lower than
66% of the 573 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.30 vs. GSK: 24.04 )
Ranked among companies with meaningful EV-to-EBITDA only.
GSK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.2 Max: 35.2
Current: 24.04
5.6
35.2
Shiller PE Ratio 17.85
GSK's Shiller PE Ratio is ranked higher than
87% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.64 vs. GSK: 17.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
GSK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.57  Med: 14.95 Max: 19.58
Current: 17.85
11.57
19.58
Current Ratio 0.88
GSK's Current Ratio is ranked lower than
90% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. GSK: 0.88 )
Ranked among companies with meaningful Current Ratio only.
GSK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.24 Max: 1.72
Current: 0.88
0.88
1.72
Quick Ratio 0.61
GSK's Quick Ratio is ranked lower than
90% of the 613 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.73 vs. GSK: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
GSK' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.99 Max: 1.32
Current: 0.61
0.61
1.32
Days Inventory 202.91
GSK's Days Inventory is ranked lower than
83% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 115.23 vs. GSK: 202.91 )
Ranked among companies with meaningful Days Inventory only.
GSK' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 188.56 Max: 202.91
Current: 202.91
167.28
202.91
Days Sales Outstanding 60.40
GSK's Days Sales Outstanding is ranked lower than
53% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 77.23 vs. GSK: 60.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
GSK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 60.4
54.62
93.9
Days Payable 141.29
GSK's Days Payable is ranked lower than
99.99% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.13 vs. GSK: 141.29 )
Ranked among companies with meaningful Days Payable only.
GSK' s Days Payable Range Over the Past 10 Years
Min: 98.94  Med: 133.85 Max: 345.65
Current: 141.29
98.94
345.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.75
GSK's Dividend Yield % is ranked higher than
97% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.24 vs. GSK: 4.75 )
Ranked among companies with meaningful Dividend Yield % only.
GSK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.83  Med: 5.12 Max: 6.24
Current: 4.75
2.83
6.24
Dividend Payout Ratio 4.17
GSK's Dividend Payout Ratio is ranked lower than
86% of the 402 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. GSK: 4.17 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GSK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 4.17
0.46
4.3
3-Year Dividend Growth Rate -1.30
GSK's 3-Year Dividend Growth Rate is ranked lower than
69% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. GSK: -1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GSK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -12.6  Med: 6.3 Max: 20.8
Current: -1.3
-12.6
20.8
Forward Dividend Yield % 4.74
GSK's Forward Dividend Yield % is ranked higher than
97% of the 649 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.64 vs. GSK: 4.74 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.94
GSK's 5-Year Yield-on-Cost % is ranked higher than
90% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.91 vs. GSK: 4.94 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GSK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.95  Med: 5.33 Max: 6.49
Current: 4.94
2.95
6.49
3-Year Average Share Buyback Ratio -0.30
GSK's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 441 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.00 vs. GSK: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GSK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.3  Med: 1.1 Max: 4.7
Current: -0.3
-20.3
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.34
GSK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
50% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.37 vs. GSK: 2.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GSK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.07  Med: 1.65 Max: 9.12
Current: 2.34
1.07
9.12
Price-to-Median-PS-Value 1.05
GSK's Price-to-Median-PS-Value is ranked higher than
59% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. GSK: 1.05 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GSK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.8  Med: 1.14 Max: 3.35
Current: 1.05
0.8
3.35
Earnings Yield (Greenblatt) % 2.49
GSK's Earnings Yield (Greenblatt) % is ranked lower than
51% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. GSK: 2.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GSK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.35 Max: 15.8
Current: 2.49
1.4
15.8
Forward Rate of Return (Yacktman) % -7.70
GSK's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 364 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.76 vs. GSK: -7.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GSK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -7.7  Med: 9.1 Max: 21
Current: -7.7
-7.7
21

More Statistics

Revenue (TTM) (Mil) $37,533
EPS (TTM) $ 0.47
Beta1.07
Short Percentage of Float0.26%
52-Week Range $37.20 - 45.58
Shares Outstanding (Mil)2,684.16

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 34,703 35,916 38,979
EPS ($) 2.52 2.58 2.88
EPS without NRI ($) 2.52 2.58 2.88
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.97%
Dividends per Share ($) 1.96 1.97 1.99
» More Articles for GSK

Headlines

Articles On GuruFocus.com
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Mar 22 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
If You Want Yield, Look to the UK Feb 19 2017 
Flood of News Presents Buying Opportunity Jan 17 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 

More From Other Websites
Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content Mar 24 2017
Exploring Novartis’s 2016 Revenue Mar 24 2017
GLAXOSMITHKLINE PLC Financials Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency Mar 23 2017
GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
GSK and Regeneron to mine gene data from 500,000 Britons Mar 22 2017
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod Mar 21 2017
Still Bullish on GlaxoSmithKline Mar 21 2017
2 safe FTSE 100 shares with dividend yields above 4% Mar 21 2017
7 Pharma Plays With Emerging Market Potential Mar 21 2017
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017 Mar 21 2017
Novartis (NVS) Announces Positive Data on Heart Failure Drug Mar 20 2017
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal Mar 20 2017
Glaxo Seeks Label Expansion for Fluarix Vaccine Mar 16 2017
Glaxo Files for Label Expansion of Influenza Vaccine in US Mar 16 2017
Is a GlaxoSmithKline plc buyout back on the cards? Mar 16 2017
GSK: New Female CEO Gets 25% Less Than Predecessor Mar 15 2017
7 Most Popular Diet Pills That Work Fast Without Exercise Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)